EP4374876A3 - Verfahren zur erzeugung von immunregulatorischen zellen in einer aus blut gewonnenen probe - Google Patents

Verfahren zur erzeugung von immunregulatorischen zellen in einer aus blut gewonnenen probe Download PDF

Info

Publication number
EP4374876A3
EP4374876A3 EP24167613.9A EP24167613A EP4374876A3 EP 4374876 A3 EP4374876 A3 EP 4374876A3 EP 24167613 A EP24167613 A EP 24167613A EP 4374876 A3 EP4374876 A3 EP 4374876A3
Authority
EP
European Patent Office
Prior art keywords
sample
immunoregulatory
cells
blood
irradiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24167613.9A
Other languages
English (en)
French (fr)
Other versions
EP4374876A2 (de
Inventor
Robert ZEISER
Petya Apostolova
Justus Duyster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therakos Development Ltd
Original Assignee
Mallinckrodt Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Pharmaceuticals Ireland Ltd filed Critical Mallinckrodt Pharmaceuticals Ireland Ltd
Publication of EP4374876A2 publication Critical patent/EP4374876A2/de
Publication of EP4374876A3 publication Critical patent/EP4374876A3/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP24167613.9A 2019-12-20 2020-12-17 Verfahren zur erzeugung von immunregulatorischen zellen in einer aus blut gewonnenen probe Pending EP4374876A3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19218724 2019-12-20
EP20833822.8A EP4077639B1 (de) 2019-12-20 2020-12-17 Verfahren zur erzeugung von immunregulatorischen zellen in einer aus blut abgeleiteten probe
PCT/EP2020/086733 WO2021122969A1 (en) 2019-12-20 2020-12-17 Method for generating immunoregulatory cells in a blood-derived sample

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP20833822.8A Division EP4077639B1 (de) 2019-12-20 2020-12-17 Verfahren zur erzeugung von immunregulatorischen zellen in einer aus blut abgeleiteten probe
EP20833822.8A Division-Into EP4077639B1 (de) 2019-12-20 2020-12-17 Verfahren zur erzeugung von immunregulatorischen zellen in einer aus blut abgeleiteten probe

Publications (2)

Publication Number Publication Date
EP4374876A2 EP4374876A2 (de) 2024-05-29
EP4374876A3 true EP4374876A3 (de) 2024-08-07

Family

ID=69005255

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20833822.8A Active EP4077639B1 (de) 2019-12-20 2020-12-17 Verfahren zur erzeugung von immunregulatorischen zellen in einer aus blut abgeleiteten probe
EP24167613.9A Pending EP4374876A3 (de) 2019-12-20 2020-12-17 Verfahren zur erzeugung von immunregulatorischen zellen in einer aus blut gewonnenen probe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP20833822.8A Active EP4077639B1 (de) 2019-12-20 2020-12-17 Verfahren zur erzeugung von immunregulatorischen zellen in einer aus blut abgeleiteten probe

Country Status (16)

Country Link
US (2) US12491248B2 (de)
EP (2) EP4077639B1 (de)
JP (2) JP7701925B2 (de)
KR (1) KR20220118404A (de)
CN (1) CN114901809B (de)
AU (1) AU2020404121A1 (de)
BR (1) BR112022010129A2 (de)
CA (1) CA3164882A1 (de)
DK (1) DK4077639T3 (de)
ES (1) ES2985816T3 (de)
FI (1) FI4077639T3 (de)
IL (2) IL326344A (de)
MX (1) MX2022006381A (de)
PL (1) PL4077639T3 (de)
PT (1) PT4077639T (de)
WO (1) WO2021122969A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115735846B (zh) * 2022-11-29 2025-09-16 复旦大学附属华山医院 磁场联合光化学诱导无创性缺血性脑卒中模型的建立方法
EP4389122A1 (de) * 2022-12-21 2024-06-26 Mallinckrodt Pharmaceuticals Ireland Limited Adiponectin allein oder in kombination mit extrakorporaler photopherese (ecp) für immunbedingte nebenwirkungen von immun-checkpoint-inhibitoren
US20240307497A1 (en) * 2022-12-21 2024-09-19 Mallinckrodt Pharmaceuticals Ireland Limited Adiponectin alone or in combination with extracorporeal photopheresis (ecp) for immune related adverse events of immune checkpoint inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002215A1 (en) * 1997-07-10 1999-01-21 Therakos, Inc. Treatment of inflammatory disorders of the bowel and urinary bladder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613322A (en) * 1982-12-08 1986-09-23 Edelson Richard Leslie Method and system for externally treating the blood
AU710242B2 (en) 1996-03-29 1999-09-16 Therakos, Inc. Photopheresis treatment of leukocytes
EP1759597B1 (de) * 2003-03-13 2009-01-21 Kirin Holdings Kabushiki Kaisha Probiotische Zusammensetzung
EP1951036A4 (de) * 2005-11-02 2009-05-27 Therakos Inc Verwendung von apoptotischen zellen ex vivo zur erzeugung von regulatorischen t-zellen
CN108578675A (zh) * 2018-03-13 2018-09-28 中国农业大学 一种小鼠嗜酸性粒细胞食管炎食物过敏模型的建立方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002215A1 (en) * 1997-07-10 1999-01-21 Therakos, Inc. Treatment of inflammatory disorders of the bowel and urinary bladder

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
APOSTOLOVA PETYA ET AL: "Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy", NEW ENGLAND JOURNAL OF MEDICINE 382:3, 16 January 2020 (2020-01-16), XP055786718, Retrieved from the Internet <URL:https://www.nejm.org/doi/pdf/10.1056/NEJMc1912274?articleTools=true> [retrieved on 20210317] *
CHEUNG VINCENT TING FUNG ET AL: "Immunotherapy induced enterocolitis and gastritis - What to do and when?", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL GASTROENTEROLOGY, BAILLIERE TINDALL, LONDON, US, vol. 48, 1 October 2020 (2020-10-01), XP086405350, ISSN: 1521-6918, [retrieved on 20201023], DOI: 10.1016/J.BPG.2020.101703 *
CHOI JUWHAN ET AL: "Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors", vol. 20, no. 1, 1 January 2020 (2020-01-01), KP, XP093173051, ISSN: 1598-2629, Retrieved from the Internet <URL:https://synapse.koreamed.org/DOIx.php?id=10.4110/in.2020.20.e9> DOI: 10.4110/in.2020.20.e9 *
JACKSON LEANNE K ET AL: "Oral health in oncology: impact of immunotherapy", SUPPORTIVE CARE IN CANCER, SPRINGER VERLAG, BERLIN, DE, vol. 23, no. 1, 13 September 2014 (2014-09-13), pages 1 - 3, XP035462786, ISSN: 0941-4355, [retrieved on 20140913], DOI: 10.1007/S00520-014-2434-6 *
NI MING ET AL: "Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis", vol. 10, 20 March 2019 (2019-03-20), pages 547, XP055786722, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436423/pdf/fimmu-10-00547.pdf> DOI: 10.3389/fimmu.2019.00547 *
PEREZ-RUIZ ELISABETH ET AL: "Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy", NATURE, MACMILLAN JOURNALS LTD., ETC, LONDON, vol. 569, no. 7756, 1 May 2019 (2019-05-01), pages 428 - 432, XP036782833, ISSN: 0028-0836, [retrieved on 20190501], DOI: 10.1038/S41586-019-1162-Y *
TRINH SARALINH ET AL: "Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines", vol. 6, no. 2, 1 June 2019 (2019-06-01), pages 154, XP055786728, ISSN: 2347-5625, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371672/pdf/APJON-6-154.pdf> DOI: 10.4103/apjon.apjon_3_19 *

Also Published As

Publication number Publication date
JP7701925B2 (ja) 2025-07-02
DK4077639T3 (da) 2024-08-19
PT4077639T (pt) 2024-09-10
JP2025126235A (ja) 2025-08-28
JP2023506413A (ja) 2023-02-16
IL326344A (en) 2026-04-01
PL4077639T3 (pl) 2024-09-30
IL293773B1 (en) 2026-03-01
EP4077639B1 (de) 2024-06-12
CN114901809A (zh) 2022-08-12
ES2985816T3 (es) 2024-11-07
EP4374876A2 (de) 2024-05-29
MX2022006381A (es) 2022-06-24
CA3164882A1 (en) 2021-06-24
US20260061057A1 (en) 2026-03-05
AU2020404121A1 (en) 2022-06-23
EP4077639A1 (de) 2022-10-26
BR112022010129A2 (pt) 2022-08-09
US20230024405A1 (en) 2023-01-26
IL293773A (en) 2022-08-01
FI4077639T3 (fi) 2024-08-22
US12491248B2 (en) 2025-12-09
KR20220118404A (ko) 2022-08-25
CN114901809B (zh) 2026-04-28
WO2021122969A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
EP4374876A3 (de) Verfahren zur erzeugung von immunregulatorischen zellen in einer aus blut gewonnenen probe
WO2016201450A3 (en) Cancer treatment and diagnosis
Kamogawa et al. A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox
EA202190474A1 (ru) Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
Mu et al. Autophagy inducer rapamycin treatment reduces IFN-I–mediated Inflammation and improves anti–HIV-1 T cell response in vivo
CR20240080A (es) Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos
Kyriakou et al. The impact of advanced patient age on mortality after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma: a retrospective study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party
EA201892542A1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
Yang et al. Taurine protects mouse spermatocytes from ionizing radiation-induced damage through activation of Nrf2/HO-1 signaling
MX2019015841A (es) Celulas inmunes defectuosas para suv39h1.
WO2008036835A3 (en) Methods and compositions for upregulation of peroxiredoxin activity
Chaabna et al. Kaposi sarcoma trends in Uganda and Zimbabwe: a sustained decline in incidence?
da Silva Oliveira et al. Photobiomodulation induces antinociception, recovers structural aspects and regulates mitochondrial homeostasis in peripheral nerve of diabetic mice
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
AU2018333275A1 (en) Treatment method
Kobashigawa et al. Relief of delayed oxidative stress by ascorbic acid can suppress radiation-induced cellular senescence in mammalian fibroblast cells
Parrondo et al. Efficacy of autologous and allogeneic hematopoietic cell transplantation in Waldenström macroglobulinemia: a systematic review and meta-analysis
EA202192964A1 (ru) Комбинированная терапия
Weber et al. Development of a virulent O’nyong’nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine
CR20220127A (es) Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
Zhang et al. Normalization by edaravone, a free radical scavenger, of irradiation-reduced endothelial nitric oxide synthase expression
HA et al. Possible ameliorative role of low dose of radiation against cisplatin induced oxidative stress and tissue damage in male rats

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 4077639

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0041000000

Ipc: C12N0005078300

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 41/00 20200101ALI20240703BHEP

Ipc: C12N 5/0783 20100101AFI20240703BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40109808

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250207

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250422

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THERAKOS DEVELOPMENT LIMITED